S2B-1 A Study of Diagnosis and Early Efficacy Prediction Biomarkers for Major Depressive Disorder

S2B-1 A Study of Diagnosis and Early Efficacy Prediction Biomarkers for Major Depressive

Disorder

袁勇贵

【期刊名称】《《神经药理学报》》 【年(卷),期】2024(008)004

【摘要】Background:Currently,diagnosis of major depressive disorder(MDD)still relies on symptoms.There are some problems for the diagnostic criteria,like low diagnostic consistency and difficulty in differentiation of MDD and bipolar depression(BD)in the early stage.In terms of treatment,there are also many problems,such as low overall efficiency,slow onset effect,and large differences between individuals.At present,there are a lot of researches on MDD biomarkers,most focus on genomics,transcriptomics,proteomics and brain imaging both from domestic and foreign counterparts,but the main research focuses are genetics and imaging.This study is mainly combine genetics and imaging to conduct the discussions of MDD diagnosis and efficacy prediction biomarkers.Methods:Proteomics mainly included patients who met the diagnostic criteria.Blood samples were taken from the participants.Serum was collected after centrifugation for serum protein concentration detection.Receiver operation curve(ROC)analysis was used to test the diagnostic and differential powers of the single serum